Twin Peaks Wealth Advisors, LLC Protagonist Therapeutics, Inc Transaction History
Twin Peaks Wealth Advisors, LLC
- $309 Billion
- Q2 2025
A detailed history of Twin Peaks Wealth Advisors, LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Twin Peaks Wealth Advisors, LLC holds 171 shares of PTGX stock, worth $11,195. This represents 0.0% of its overall portfolio holdings.
Number of Shares
171Holding current value
$11,195% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PTGX
# of Institutions
297Shares Held
67.4MCall Options Held
290KPut Options Held
318K-
Farallon Capital Management LLC San Francisco, CA6.17MShares$404 Million1.53% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$377 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.76MShares$377 Million4.89% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.36MShares$285 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.25MShares$213 Million6.36% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $3.21B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...